Monoclonal Antibody Development Targeting Costimulatory Pathways for Autoimmune Diseases

Autoimmune diseases (ADs) are caused by many factors. Costimulatory pathways play an important role in the development of autoimmune diseases. Therefore, exploring this pathway can promote the treatment of autoimmune diseases. With the advantage of broad technological expertise in the development of monoclonal antibody (mAb), Creative Biolabs offers monoclonal antibody development services targeting costimulatory pathways to promote the treatment of autoimmune diseases.

Introduction of Autoimmune Diseases and Costimulatory Pathways

After breaking the self-tolerance of the immune system, the development of ADs involves many different molecules. Costimulatory pathways initiate and perpetuate proinflammatory processes by sustaining cognate interaction between activated T lymphocytes (T) cells and antigen-presenting cells (APCs). Costimulatory pathways play a very important role in some ADs such as rheumatoid arthritis (RA), psoriasis, and lupus erythematosus (LE).

Fig.1 Expression of costimulation molecules in different stages of immune activation and their concerted effector functions.¹

Monoclonal Antibody Development Targeting Costimulatory Pathways for Autoimmune Diseases

Some studies showed that blocking the costimulatory pathway by mAb could ease autoimmune diseases. In a mouse model, blockading the cluster of differentiation (CD) 80 by mAb was explored in the treatment of lupus-like disease. The results showed that mAb against CD80 can ease inflammatory response and severity of lupus-like signs. Another study showed that anti-b7h mAb seems to play a role in the treatment of nephropathy. Scientists found that blockading of B7-related peptide 1 (B7RP1) with anti-B7h mAb can reduce the degree of glomerulonephritis and prolong the survival of the mice.

Custom Services of Monoclonal Antibody Development Targeting Costimulatory Pathways

Although autoimmune diseases can be treated by drugs, they usually have great side effects and require long-term medication. Therefore, the development of new drugs is imminent. Blocking the costimulatory pathway by mAb is an available way for the treatment of autoimmune diseases. To help customers develop new therapeutic strategy against ADs, Creative Biolabs provides the mAb development services targeting costimulatory pathways, including but not limited to:

• Monoclonal Antibody Development Targeting CD80/86-CD28 for Autoimmune Diseases
• Monoclonal Antibody Development Targeting CD40-CD40L for Autoimmune Diseases
• Monoclonal Antibody Development Targeting CD137-CD137L for Autoimmune Diseases
• Monoclonal Antibody Development Targeting CD70-CD27 for Autoimmune Diseases
• Monoclonal Antibody Development Targeting OX40-OX40L for Autoimmune Diseases
• Monoclonal Antibody Development Targeting ICOS-B7RP1 for Autoimmune Diseases

Driven by the fact that mAb has a significant therapeutic effect on autoimmune diseases, Creative Biolabs provides mAb development services targeting costimulatory pathways to promote the treatment of autoimmune diseases. We have broad technological expertise that allows us to develop original formulations and design solutions that are easy to use in research. If you are interested in our services, please contact us.

Reference

1. Yee, K. N.; Anselm, M. Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus. Clinical & Developmental Immunology. 2013, 2013: 245928. Distributed under CC BY 3.0, without modification.

For Research Use Only | Not For Clinical Use